180 Wealth Advisors LLC Acquires 60,213 Shares of Organon & Co. $OGN

180 Wealth Advisors LLC raised its holdings in shares of Organon & Co. (NYSE:OGN) by 35.9% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 227,971 shares of the company’s stock after acquiring an additional 60,213 shares during the period. 180 Wealth Advisors LLC’s holdings in Organon & Co. were worth $1,366,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Royal Bank of Canada raised its holdings in shares of Organon & Co. by 53.4% in the 1st quarter. Royal Bank of Canada now owns 360,862 shares of the company’s stock valued at $5,374,000 after acquiring an additional 125,648 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Organon & Co. by 126.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,435,198 shares of the company’s stock valued at $21,370,000 after acquiring an additional 801,307 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Organon & Co. by 2.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,042,991 shares of the company’s stock worth $15,530,000 after purchasing an additional 26,640 shares in the last quarter. Focus Partners Wealth grew its holdings in shares of Organon & Co. by 33.2% during the first quarter. Focus Partners Wealth now owns 55,875 shares of the company’s stock worth $832,000 after purchasing an additional 13,925 shares in the last quarter. Finally, XTX Topco Ltd bought a new position in shares of Organon & Co. in the second quarter worth approximately $107,000. 77.43% of the stock is currently owned by institutional investors.

Organon & Co. Price Performance

Shares of Organon & Co. stock opened at $13.52 on Monday. Organon & Co. has a 52-week low of $5.69 and a 52-week high of $13.60. The stock has a market capitalization of $3.55 billion, a price-to-earnings ratio of 14.53, a price-to-earnings-growth ratio of 1.25 and a beta of 1.54. The company has a fifty day moving average of $13.43 and a 200-day moving average of $9.78. The company has a debt-to-equity ratio of 9.47, a quick ratio of 1.42 and a current ratio of 1.97.

Organon & Co. (NYSE:OGN) last issued its earnings results on Thursday, April 30th. The company reported $0.71 EPS for the quarter, missing analysts’ consensus estimates of $0.83 by ($0.12). The business had revenue of $1.46 billion during the quarter, compared to analysts’ expectations of $1.49 billion. Organon & Co. had a return on equity of 99.95% and a net margin of 3.99%.Organon & Co.’s revenue for the quarter was down 3.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.02 EPS. Equities research analysts expect that Organon & Co. will post 3.23 EPS for the current year.

Organon & Co. Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 11th. Stockholders of record on Monday, May 11th were paid a dividend of $0.02 per share. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend was Monday, May 11th. Organon & Co.’s dividend payout ratio (DPR) is 8.60%.

Insider Activity at Organon & Co.

In related news, SVP Lynette Holzbaur acquired 26,448 shares of the firm’s stock in a transaction dated Wednesday, May 6th. The shares were purchased at an average price of $13.35 per share, for a total transaction of $353,080.80. Following the completion of the acquisition, the senior vice president owned 52,851 shares in the company, valued at approximately $705,560.85. This represents a 100.17% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 1.62% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on OGN shares. Piper Sandler raised shares of Organon & Co. from an “underweight” rating to a “neutral” rating and raised their target price for the company from $5.00 to $14.00 in a research note on Tuesday, April 28th. Zacks Research raised shares of Organon & Co. from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 14th. BNP Paribas Exane reissued a “neutral” rating and issued a $14.00 price target (up from $12.00) on shares of Organon & Co. in a report on Wednesday, April 29th. Finally, Weiss Ratings upgraded shares of Organon & Co. from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, May 15th. Five analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Organon & Co. has a consensus rating of “Reduce” and an average price target of $11.40.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.